Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission-Niger Experience.
eradication
immunizations
poliomyelitis
seroprevalence
vaccine-preventable diseases
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
03
2021
accepted:
03
05
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
Outbreaks of vaccine-derived poliovirus type 2 (VDPV2) continue to expand across Africa. We conducted a serological survey of polio antibodies in high-polio risk areas of Niger to assess risk of poliovirus outbreaks. Children between 1 and 5 years of age were enrolled from structures randomly selected using satellite imaging enumeration in Diffa Province, Niger, in July 2019. After obtaining informed consent, dried blood spot cards were collected. Neutralizing antibodies against 3 poliovirus serotypes were detected using microneutralization assay at the Centers for Disease Control and Prevention. We obtained analyzable data from 309/322 (95.9%) enrolled children. Seroprevalence of polio antibodies was 290/309 (93.9%), 272/309 (88.0%), and 254/309 (82.2%) for serotypes 1, 2, and 3, respectively. For serotypes 1 and 2, the seroprevalence did not significantly change with age ( With type 2 seroprevalence close to 90%, the risk of emergence of new cVDPV2 outbreaks in Niger is low; however, the risk of cVDPV2 importations from neighboring countries leading to local transmission persists. Niger should maintain its outbreak response readiness capacity and further strengthen its routine immunization.
Sections du résumé
BACKGROUND
BACKGROUND
Outbreaks of vaccine-derived poliovirus type 2 (VDPV2) continue to expand across Africa. We conducted a serological survey of polio antibodies in high-polio risk areas of Niger to assess risk of poliovirus outbreaks.
METHODS
METHODS
Children between 1 and 5 years of age were enrolled from structures randomly selected using satellite imaging enumeration in Diffa Province, Niger, in July 2019. After obtaining informed consent, dried blood spot cards were collected. Neutralizing antibodies against 3 poliovirus serotypes were detected using microneutralization assay at the Centers for Disease Control and Prevention.
RESULTS
RESULTS
We obtained analyzable data from 309/322 (95.9%) enrolled children. Seroprevalence of polio antibodies was 290/309 (93.9%), 272/309 (88.0%), and 254/309 (82.2%) for serotypes 1, 2, and 3, respectively. For serotypes 1 and 2, the seroprevalence did not significantly change with age (
CONCLUSIONS
CONCLUSIONS
With type 2 seroprevalence close to 90%, the risk of emergence of new cVDPV2 outbreaks in Niger is low; however, the risk of cVDPV2 importations from neighboring countries leading to local transmission persists. Niger should maintain its outbreak response readiness capacity and further strengthen its routine immunization.
Identifiants
pubmed: 34295940
doi: 10.1093/ofid/ofab210
pii: ofab210
pmc: PMC8291560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab210Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Epidemiol Glob Health. 2015 Dec;5(4 Suppl 1):S67-71
pubmed: 26166424
Vaccine. 2012 Nov 6;30(48):6759-65
pubmed: 23000220
Afr Health Sci. 2014 Mar;14(1):125-30
pubmed: 26060468
Annu Rev Microbiol. 2005;59:587-635
pubmed: 16153180
J Infect Dis. 2014 Nov 1;210 Suppl 1:S225-33
pubmed: 25316839
J Med Virol. 2012 Apr;84(4):691-6
pubmed: 22337311
J Infect Dis. 2014 Nov 1;210 Suppl 1:S243-51
pubmed: 25316842
J Infect Dis. 2014 Nov 1;210 Suppl 1:S434-8
pubmed: 25316865
MMWR Morb Mortal Wkly Rep. 2016 Sep 09;65(35):934-8
pubmed: 27606675
Methods Mol Biol. 2016;1387:145-76
pubmed: 26983734
J Infect Dis. 2016 May 1;213 Suppl 3:S124-30
pubmed: 26908720
J Virol. 2013 May;87(9):4907-22
pubmed: 23408630
Science. 2020 Apr 24;368(6489):401-405
pubmed: 32193361
Vaccine. 2016 Sep 30;34(42):5125-5131
pubmed: 27591950
Heliyon. 2018 Mar 07;4(3):e00563
pubmed: 29560473
J Infect Dis. 2014 Nov 1;210 Suppl 1:S234-42
pubmed: 25316841
Vaccine. 2018 Feb 14;36(8):1027-1031
pubmed: 29358054
Vaccine. 2015 Jun 4;33(24):2757-63
pubmed: 25917673
Vaccine. 2009 May 5;27(20):2649-52
pubmed: 19428874